Topic: rheumatoid arthritis
Painted as the follow-up drug to Humira, AbbVie’s JAK med Rinvoq has blockbuster hopes in mind. An early nod in the EU could help it reach that goal.
ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.
Just days after releasing a report suggesting that three JAK inhibitors for rheumatoid arthritis wouldn't be cost-effective, ICER is backtracking.
JAK inhibitors to treat rheumatoid arthritis, like AbbVie's Humira follow-up, Rinvoq, may not be cost effective, ICER says in a new report.
The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.
AbbVie is suffering from Humira biosims in Europe, but new launches could help the company backfill those losses—and Skyrizi's new numbers show how.
Gilead will need to build out a commercial immunology team as its JAK inhibitor filgotinib nears an FDA filing.
Even as AbbVie’s industry-leading Humira faces its eventual sales decline, the company can be thankful that it has two out of the three top launches of 2019, based on 2024 sales.
Pfizer’s Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s high-dose hopes in RA. Could new data help the cause?
Eli Lilly and Incyte’s Olumiant path has been a precarious one, with the FDA repeatedly knocking the drug’s larger dose. Can new safety data help?